Novel drugs for the treatment of multiple myeloma

The outcome of patients with multiple myeloma (MM) treated with conventional chemotherapy with or without high-dose therapy/autologous stem cell transplantation (SCT) has not been satisfactory, with median survivals ranging from 2 to 3 years for older patients and from 5 to 6 years for younger

[1]  J. Bladé,et al.  Hematopoietic stem cell transplantation for multiple myeloma beyond 2010. , 2010, Blood.

[2]  A. Zannettino,et al.  Hypoxia-inducible factor-2 is a novel regulator of aberrant CXCL12 expression in multiple myeloma plasma cells , 2010, Haematologica.

[3]  C. Bokemeyer,et al.  Cancer-testis antigens MAGE-C1/CT7 and MAGE-A3 promote the survival of multiple myeloma cells , 2010, Haematologica.

[4]  P. Atadja,et al.  In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma , 2010, Haematologica.

[5]  M. Boccadoro,et al.  Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  B. Pégourié,et al.  Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myelome (IFM). , 2010, Blood.

[7]  M. Dimopoulos,et al.  A Phase III Study to Determine the Efficacy and Safety of Lenalidomide in Combination with Melphalan and Prednisone (MPR) in Elderly Patients with Newly Diagnosed Multiple Myeloma , 2009 .

[8]  M. Baccarani,et al.  A Phase III Study of Double Autotransplantation Incorporating Bortezomib-Thalidomide-Dexamethasone (VTD) or Thalidomide-Dexamethasone (TD) for Multiple Myeloma: Superior Clinical Outcomes with VTD Compared to TD. , 2009 .

[9]  M. Terol,et al.  Thalidomide / Dexamethasone (TD) Vs. Bortezomib (Velcade)â/Thalidomide / Dexamethasone (VTD) Vs. VBMCP/VBAD/Velcadeâ as Induction Regimens Prior Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma (MM): Results of a Phase III PETHEMA/GEM Trial. , 2009 .

[10]  P. Moreau,et al.  High Complete and Very Good Partial Response Rates with Bortezomib—Dexamethasone as Induction Prior to ASCT in Newly Diagnosed Patients with High-Risk Myeloma: Results of the IFM2005-01 Phase 3 Trial. , 2009 .

[11]  A. Jack,et al.  Five-Year Follow-up of Monoclonal B-Cell Lymphocytosis (MBL) in Individuals with a Normal Blood Count: Expansion of the Abnormal B-Cell Compartment but No Progressive Disease. , 2009 .

[12]  Louise N. Winteringham,et al.  Hls5, a Novel Ubiquitin E3 Ligase, Modulates Levels of Sumoylated GATA-1. , 2009 .

[13]  J. Harousseau.  Hematopoietic stem cell transplantation in multiple myeloma. , 2009, Journal of the National Comprehensive Cancer Network : JNCCN.

[14]  Marcos González,et al.  Molecular stratification model for prognosis in cytogenetically normal acute myeloid leukemia. , 2009, Blood.

[15]  J. Bladé,et al.  Changing paradigms in the treatment of multiple myeloma , 2009, Haematologica.

[16]  L. Escoda,et al.  Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  A. Pandiella,et al.  New drugs in multiple myeloma: mechanisms of action and phase I/II clinical findings. , 2008, The Lancet. Oncology.

[18]  A. Órfão,et al.  Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. , 2008, Blood.

[19]  J. Bladé,et al.  Advances in therapy of multiple myeloma , 2008, Current opinion in oncology.

[20]  Bin Jiang,et al.  Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. , 2008, The New England journal of medicine.

[21]  D. Dabkara,et al.  Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma , 2008 .

[22]  Alessandro Corso,et al.  Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. , 2007, The New England journal of medicine.

[23]  Michael Wang,et al.  Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. , 2007, The New England journal of medicine.

[24]  A. Oriol,et al.  Phase II PETHEMA trial of alternating bortezomib and dexamethasone as induction regimen before autologous stem-cell transplantation in younger patients with multiple myeloma: efficacy and clinical implications of tumor response kinetics. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  B. Barlogie,et al.  Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3 , 2007, British journal of haematology.

[26]  K. Pantel,et al.  Promoter Demethylation and Histone Acetylation Mediate Gene Expression of MAGE-A1, -A2, -A3, and -A12 in Human Cancer Cells , 2006, Molecular Cancer Research.

[27]  Lloyd J. Old,et al.  Cancer/testis antigens, gametogenesis and cancer , 2005, Nature Reviews Cancer.

[28]  Hartmut Goldschmidt,et al.  Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. , 2005, The New England journal of medicine.

[29]  R. Champlin,et al.  Impact of complete remission with intensive therapy in patients with responsive multiple myeloma , 2001, Bone Marrow Transplantation.

[30]  R. Fonseca,et al.  Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. , 2010, The Lancet. Oncology.

[31]  D. Chauhan,et al.  Bone marrow microenvironment and the identification of new targets for myeloma therapy , 2009, Leukemia.

[32]  A. Órfão,et al.  Multiparameter flow cytometry remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation , 2008 .

[33]  F. Storti.  Ferrata Storti Foundation , 2008 .

[34]  B. Pégourié,et al.  Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study. , 2006, Haematologica.

[35]  J. Esteve,et al.  Extramedullary multiple myeloma escapes the effect of thalidomide. , 2004, Haematologica.

[36]  E. Giné,et al.  High-dose therapy/autologous stem cell transplantation in patients with chemosensitive multiple myeloma: predictors of complete remission , 2004, Bone Marrow Transplantation.